The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Determination of the possibilities of targeted therapy for gastric cancer

Authors:

Zavalishina L.É., Andreeva Yu.Yu., Frank G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2012;74(4): 21‑27

Read: 2575 times

Download PDF (RU)
Contact the author
Table of contents

DETERMINATION OF THE POSSIBILITIES OF TARGETED THERAPY FOR GASTRIC CANCER
DETERMINATION OF THE POSSIBILITIES OF TARGETED THERAPY FOR GASTRIC CANCER

To cite this article:

Zavalishina LÉ, Andreeva YuYu, Frank GA. Determination of the possibilities of targeted therapy for gastric cancer. Russian Journal of Archive of Pathology. 2012;74(4):21‑27. (In Russ.)

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cardiac myxoma: biological features, morphology, differential diagnosis. Russian Journal of Archive of Pathology. 2024;(6):74-81
Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99
A clinical case of successful treatment of stage IV gastric cancer. P.A. Herzen Journal of Onco­logy. 2024;(5):54-58
Immu­nohistochemical features and pathogenesis of hype­rextensible eyelids. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):25-33
Pancreaticoduodenectomy combined with multivisceral rese­ctions. Piro­gov Russian Journal of Surgery. 2024;(11):77-83
Expe­rience of successful treatment of leaks of high esophageal-intestinal anastomoses after gastrectomy by means of video-assisted thoracoscopic debridement and cycles of vacuum active aspi­ration system. P.A. Herzen Journal of Onco­logy. 2024;(6):63-69
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
Differential Diagnosis of Perianal Skin Neoplasms. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):673-678
Clinical Case of HIV-Associated Kaposi’s Sarcoma. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):782-786
New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38
Abstract:

The objective of the investigation whose results are given in the paper was to compare a few HER2 testing techniques (immunohistochemistry, fluorescence in situ hybridization, and silver in situ hybridization) for adenocarcinomas of the stomach and esophagogastric junction. Different antibody clones and in situ hybridization kits were comparatively analyzed. Recommendations for the use of different testing methods and for the interpretation of their results are given.

Keywords:

gastric cancer
immunohistochemistry
in situ hybridization

Authors:

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Close metadata

References:

  1. Davydov M.I., Ter-Ovanesov M.D. Rak proksimal'nogo otdela zheludka: sovremennaya klassifikatsiya, taktika khirurgicheskogo lecheniya, faktory prognoza. Rus med zhurn: Onkologiya 2008; 16: 13: 914-921.
  2. Lud A.N., Vakhabova Yu.V., Semenov N.N., Gan'shina I.P., Stepanova E.V. Znachenie HER2 statusa pri rake zheludka. Sovrem onkol 2010; 2: 3-6.
  3. Bang Y.-J., van Cutsem E.V., Feyereislova A., Chung H.C. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 9742: 687-697.
  4. Barros-Silva J.D., Leitão D., Afonso L. et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 3: 487-493.
  5. Boers J.E., Meeuwissen H., Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 3: 383-394.
  6. García-García E., Gómez-Martín C., Angulo B. et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology 2011; 59: 1: 8-17.
  7. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 9: 1523-1529.
  8. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009; 101: 19: 1306-1307.
  9. Hoffman M., Stoss O., Shi D. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
  10. Kim M.A., Jung E.J., Lee H.S., Lee H.E., Jeon Y.K., Yang H.K., Kim W.H. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-1393.
  11. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
  12. Moelans C.B., van Diest P.J., Milne A.N., Offerhaus G.J. HER-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathol Res Int 2010; 2011: 674182.
  13. Park D.I., Yun J.W., Park J.H. et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379.
  14. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
  15. Popesku N.C., King C.R., Kraus M.H. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4: 3: 362-366.
  16. Slamon D.J., Leyland-Jones B. et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001; 344: 11: 783-792.
  17. Souza Rh.F., Spechler St.J. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005; 55: 334-351.
  18. Takehana T., Kunitomo K., Kono K., Kitahara F., Iizuka H., Matsumoto Y., Fujino M.A., Ooi A. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-837.
  19. Tanner M., Hollmen M., Juntilla T. et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 2: 273-278.
  20. Yano T., Ochiai A., Doi T. et al. Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 2004; 22: 14S (abstr. 4053).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.